山東黃金(01787.HK):山東黃金香港宣佈延長要約期
格隆匯1月12日丨山東黃金(01787.HK)公佈,有關要約收購及認購卡帝諾資源有限公司股份事項,為進一步推進要約交易,山東黃金香港於2021年1月12日宣佈延長要約期,故要約交易直至2021年1月19日下午七時正(悉尼時間)前繼續可被接納。除該等公吿及上述所披露者外,《要約實施協議》及要約交易的條款及條件截至本公吿日期概無其他重大變動。
截至2021年1月11日,已接獲接納項下的卡帝諾股份數目為431,675,403股卡帝諾股份,佔卡帝諾已發行股本約77.87%,而山東黃金香港一共於卡帝諾已發行股本約82.56%中擁有相關權益(包括已接獲接納項下卡帝諾股份的相關權益)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.